| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burnout, Professional | 27 | 2026 | 488 | 7.270 |
Why?
|
| Critical Care | 46 | 2026 | 702 | 7.000 |
Why?
|
| Intensive Care Units | 58 | 2026 | 924 | 6.650 |
Why?
|
| Critical Illness | 39 | 2026 | 900 | 5.660 |
Why?
|
| Health Personnel | 12 | 2026 | 757 | 3.760 |
Why?
|
| Respiration, Artificial | 35 | 2025 | 714 | 3.700 |
Why?
|
| Survivors | 24 | 2026 | 523 | 3.600 |
Why?
|
| Respiratory Insufficiency | 13 | 2024 | 327 | 3.340 |
Why?
|
| Alcoholism | 25 | 2025 | 826 | 2.890 |
Why?
|
| Deglutition Disorders | 9 | 2020 | 154 | 2.870 |
Why?
|
| Physical Therapy Modalities | 13 | 2026 | 337 | 2.840 |
Why?
|
| Acute Lung Injury | 19 | 2021 | 307 | 2.810 |
Why?
|
| Nursing Staff, Hospital | 9 | 2021 | 143 | 2.730 |
Why?
|
| Neuromuscular Blockade | 8 | 2025 | 53 | 2.660 |
Why?
|
| Critical Care Nursing | 6 | 2020 | 48 | 2.570 |
Why?
|
| Stress, Psychological | 14 | 2026 | 1151 | 2.540 |
Why?
|
| Sepsis | 23 | 2023 | 664 | 2.530 |
Why?
|
| Deglutition | 5 | 2020 | 73 | 2.300 |
Why?
|
| Third-Party Consent | 4 | 2025 | 21 | 2.230 |
Why?
|
| Resilience, Psychological | 7 | 2020 | 150 | 2.190 |
Why?
|
| Informed Consent | 6 | 2025 | 199 | 2.070 |
Why?
|
| Respiratory Aspiration | 4 | 2020 | 32 | 1.920 |
Why?
|
| Airway Extubation | 5 | 2020 | 60 | 1.750 |
Why?
|
| Neuromuscular Blocking Agents | 6 | 2020 | 28 | 1.730 |
Why?
|
| Humans | 248 | 2026 | 145783 | 1.680 |
Why?
|
| Early Ambulation | 3 | 2024 | 25 | 1.680 |
Why?
|
| Hospital Mortality | 19 | 2025 | 1038 | 1.570 |
Why?
|
| Research Personnel | 6 | 2025 | 185 | 1.550 |
Why?
|
| Polyneuropathies | 5 | 2018 | 57 | 1.510 |
Why?
|
| Middle Aged | 114 | 2025 | 36309 | 1.500 |
Why?
|
| Art Therapy | 2 | 2024 | 23 | 1.470 |
Why?
|
| Intubation, Intratracheal | 5 | 2020 | 327 | 1.420 |
Why?
|
| Biomedical Research | 4 | 2025 | 719 | 1.410 |
Why?
|
| Patient Discharge | 10 | 2023 | 995 | 1.400 |
Why?
|
| Male | 133 | 2026 | 73010 | 1.320 |
Why?
|
| Female | 137 | 2026 | 79045 | 1.310 |
Why?
|
| Delirium | 5 | 2014 | 105 | 1.250 |
Why?
|
| Adaptation, Psychological | 8 | 2023 | 719 | 1.230 |
Why?
|
| APACHE | 8 | 2017 | 68 | 1.210 |
Why?
|
| Leadership | 2 | 2026 | 402 | 1.210 |
Why?
|
| Point-of-Care Testing | 2 | 2020 | 35 | 1.120 |
Why?
|
| Aged | 67 | 2025 | 26217 | 1.070 |
Why?
|
| Muscle Weakness | 6 | 2018 | 92 | 1.060 |
Why?
|
| Neural Conduction | 4 | 2018 | 92 | 1.050 |
Why?
|
| Tidal Volume | 6 | 2025 | 109 | 1.020 |
Why?
|
| Length of Stay | 11 | 2021 | 1350 | 1.000 |
Why?
|
| Adult | 87 | 2025 | 40881 | 0.990 |
Why?
|
| Stress Disorders, Post-Traumatic | 11 | 2026 | 890 | 0.980 |
Why?
|
| Geriatric Assessment | 4 | 2013 | 240 | 0.950 |
Why?
|
| Prospective Studies | 29 | 2024 | 8078 | 0.910 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 883 | 0.910 |
Why?
|
| Workplace | 6 | 2022 | 272 | 0.900 |
Why?
|
| United States | 45 | 2026 | 16126 | 0.900 |
Why?
|
| Pulmonary Medicine | 4 | 2014 | 78 | 0.850 |
Why?
|
| Workload | 2 | 2024 | 169 | 0.850 |
Why?
|
| Frail Elderly | 4 | 2013 | 136 | 0.830 |
Why?
|
| Trust | 2 | 2025 | 158 | 0.820 |
Why?
|
| Patient Acuity | 1 | 2024 | 48 | 0.790 |
Why?
|
| Hypnotics and Sedatives | 5 | 2025 | 222 | 0.790 |
Why?
|
| Clinical Trials as Topic | 5 | 2024 | 1062 | 0.790 |
Why?
|
| Risk Factors | 34 | 2020 | 10919 | 0.780 |
Why?
|
| Postoperative Complications | 7 | 2014 | 2977 | 0.780 |
Why?
|
| Alcohol-Related Disorders | 5 | 2015 | 121 | 0.780 |
Why?
|
| Hospitalization | 13 | 2025 | 2461 | 0.780 |
Why?
|
| Ventilators, Mechanical | 3 | 2025 | 71 | 0.770 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2013 | 112 | 0.770 |
Why?
|
| Patient Admission | 3 | 2025 | 220 | 0.740 |
Why?
|
| Societies, Medical | 6 | 2021 | 900 | 0.730 |
Why?
|
| Teaching Rounds | 1 | 2024 | 74 | 0.730 |
Why?
|
| Job Satisfaction | 6 | 2026 | 238 | 0.730 |
Why?
|
| Family | 4 | 2023 | 685 | 0.720 |
Why?
|
| Decision Making | 5 | 2025 | 982 | 0.710 |
Why?
|
| Shock, Septic | 4 | 2022 | 227 | 0.700 |
Why?
|
| Wounds and Injuries | 5 | 2014 | 962 | 0.680 |
Why?
|
| Cohort Studies | 21 | 2022 | 6033 | 0.660 |
Why?
|
| Positive-Pressure Respiration | 4 | 2023 | 115 | 0.650 |
Why?
|
| Tryptophan | 2 | 2014 | 182 | 0.630 |
Why?
|
| Elective Surgical Procedures | 5 | 2014 | 203 | 0.630 |
Why?
|
| Glutathione | 5 | 2007 | 370 | 0.610 |
Why?
|
| Blood Component Transfusion | 2 | 2011 | 102 | 0.600 |
Why?
|
| Symptom Assessment | 1 | 2020 | 136 | 0.580 |
Why?
|
| Speech Therapy | 1 | 2019 | 21 | 0.580 |
Why?
|
| Epidemics | 2 | 2019 | 96 | 0.570 |
Why?
|
| Pulmonary Alveoli | 6 | 2013 | 387 | 0.570 |
Why?
|
| Logistic Models | 11 | 2018 | 2139 | 0.560 |
Why?
|
| Career Choice | 3 | 2015 | 235 | 0.550 |
Why?
|
| Multiple Organ Failure | 5 | 2009 | 120 | 0.540 |
Why?
|
| Atracurium | 4 | 2019 | 14 | 0.540 |
Why?
|
| Risk Assessment | 11 | 2020 | 3752 | 0.530 |
Why?
|
| Erythrocyte Transfusion | 3 | 2011 | 225 | 0.530 |
Why?
|
| Deep Sedation | 1 | 2018 | 16 | 0.530 |
Why?
|
| Surveys and Questionnaires | 14 | 2025 | 6085 | 0.530 |
Why?
|
| Models, Organizational | 2 | 2015 | 144 | 0.530 |
Why?
|
| Occupational Therapy | 1 | 2019 | 109 | 0.510 |
Why?
|
| Organizational Culture | 2 | 2015 | 162 | 0.510 |
Why?
|
| Personnel Selection | 2 | 2015 | 91 | 0.510 |
Why?
|
| Electromyography | 2 | 2018 | 419 | 0.500 |
Why?
|
| Ethics, Nursing | 1 | 2016 | 7 | 0.480 |
Why?
|
| Blood-Air Barrier | 2 | 2008 | 11 | 0.480 |
Why?
|
| Pulmonary Fibrosis | 5 | 2014 | 395 | 0.470 |
Why?
|
| Patient Readmission | 7 | 2019 | 773 | 0.470 |
Why?
|
| Cognition | 2 | 2024 | 1271 | 0.460 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2007 | 98 | 0.460 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 920 | 0.460 |
Why?
|
| Personal Satisfaction | 2 | 2015 | 221 | 0.460 |
Why?
|
| Occupational Stress | 3 | 2021 | 46 | 0.460 |
Why?
|
| Interviews as Topic | 4 | 2026 | 916 | 0.450 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 130 | 0.440 |
Why?
|
| Physical Examination | 1 | 2016 | 244 | 0.440 |
Why?
|
| Algorithms | 4 | 2025 | 1851 | 0.440 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2013 | 185 | 0.440 |
Why?
|
| Pneumonia | 6 | 2023 | 636 | 0.430 |
Why?
|
| Retrospective Studies | 28 | 2025 | 17330 | 0.430 |
Why?
|
| Aged, 80 and over | 20 | 2022 | 8347 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2025 | 1372 | 0.430 |
Why?
|
| Lung Diseases | 4 | 2011 | 782 | 0.420 |
Why?
|
| Institutionalization | 2 | 2011 | 12 | 0.420 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 46 | 0.410 |
Why?
|
| Muscle Strength | 2 | 2017 | 332 | 0.410 |
Why?
|
| Depression | 6 | 2026 | 1559 | 0.410 |
Why?
|
| Intracranial Hemorrhages | 1 | 2015 | 106 | 0.410 |
Why?
|
| Mindfulness | 3 | 2024 | 136 | 0.400 |
Why?
|
| Stem Cells | 3 | 2015 | 630 | 0.400 |
Why?
|
| Rectum | 2 | 2013 | 182 | 0.400 |
Why?
|
| Health Promotion | 1 | 2020 | 775 | 0.400 |
Why?
|
| Mobile Applications | 3 | 2026 | 199 | 0.390 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.390 |
Why?
|
| Incidence | 14 | 2013 | 2934 | 0.390 |
Why?
|
| Alcoholic Intoxication | 1 | 2014 | 76 | 0.380 |
Why?
|
| Anxiety | 6 | 2026 | 1122 | 0.380 |
Why?
|
| Recovery of Function | 1 | 2017 | 716 | 0.380 |
Why?
|
| Global Health | 1 | 2016 | 403 | 0.370 |
Why?
|
| Speech-Language Pathology | 1 | 2012 | 24 | 0.370 |
Why?
|
| Cross Infection | 3 | 2011 | 260 | 0.370 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 444 | 0.370 |
Why?
|
| Colon | 2 | 2013 | 309 | 0.360 |
Why?
|
| Biomarkers | 12 | 2024 | 4302 | 0.360 |
Why?
|
| Focus Groups | 2 | 2025 | 572 | 0.360 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 2123 | 0.360 |
Why?
|
| Nursing | 1 | 2012 | 37 | 0.350 |
Why?
|
| Transfusion Reaction | 2 | 2009 | 61 | 0.350 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2017 | 574 | 0.350 |
Why?
|
| Qualitative Research | 4 | 2026 | 1683 | 0.350 |
Why?
|
| Health Care Costs | 3 | 2020 | 425 | 0.350 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 62 | 0.340 |
Why?
|
| Treatment Outcome | 17 | 2022 | 11794 | 0.340 |
Why?
|
| Cooperative Behavior | 5 | 2016 | 463 | 0.330 |
Why?
|
| Prevalence | 8 | 2025 | 2875 | 0.330 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 5925 | 0.330 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 2 | 2018 | 31 | 0.320 |
Why?
|
| Hospital Costs | 1 | 2011 | 125 | 0.320 |
Why?
|
| Health Services Accessibility | 2 | 2018 | 1101 | 0.320 |
Why?
|
| Psychomotor Agitation | 1 | 2011 | 69 | 0.320 |
Why?
|
| Multivariate Analysis | 9 | 2018 | 1547 | 0.310 |
Why?
|
| Patient Education as Topic | 2 | 2016 | 777 | 0.310 |
Why?
|
| Program Evaluation | 1 | 2014 | 944 | 0.310 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 286 | 0.310 |
Why?
|
| Extravascular Lung Water | 3 | 2009 | 9 | 0.310 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 65 | 0.310 |
Why?
|
| Exercise Test | 2 | 2014 | 630 | 0.310 |
Why?
|
| Patient Preference | 1 | 2012 | 223 | 0.310 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.300 |
Why?
|
| Asthma | 4 | 2022 | 1797 | 0.300 |
Why?
|
| Secondary Prevention | 1 | 2011 | 251 | 0.300 |
Why?
|
| Brain Injuries | 1 | 2015 | 507 | 0.300 |
Why?
|
| Leptin | 1 | 2011 | 248 | 0.300 |
Why?
|
| Congresses as Topic | 1 | 2011 | 224 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2026 | 1752 | 0.300 |
Why?
|
| Mental Health | 1 | 2016 | 796 | 0.300 |
Why?
|
| Pneumonia, Bacterial | 2 | 2007 | 113 | 0.300 |
Why?
|
| Drug Overdose | 1 | 2014 | 375 | 0.300 |
Why?
|
| Mass Screening | 1 | 2018 | 1361 | 0.290 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 138 | 0.290 |
Why?
|
| Bone Development | 3 | 1997 | 52 | 0.290 |
Why?
|
| Cognition Disorders | 2 | 2016 | 544 | 0.290 |
Why?
|
| ROC Curve | 5 | 2017 | 618 | 0.290 |
Why?
|
| Homeostasis | 2 | 2003 | 644 | 0.290 |
Why?
|
| Colorado | 8 | 2018 | 4556 | 0.280 |
Why?
|
| Pleural Diseases | 1 | 2008 | 23 | 0.280 |
Why?
|
| Lung | 9 | 2017 | 4116 | 0.280 |
Why?
|
| Time Factors | 9 | 2017 | 7134 | 0.280 |
Why?
|
| Sensitivity and Specificity | 5 | 2017 | 2000 | 0.280 |
Why?
|
| Patient Positioning | 2 | 2022 | 70 | 0.270 |
Why?
|
| Physicians | 3 | 2022 | 956 | 0.270 |
Why?
|
| Occupational Exposure | 1 | 2012 | 355 | 0.270 |
Why?
|
| Comorbidity | 9 | 2020 | 1662 | 0.270 |
Why?
|
| Bronchoalveolar Lavage Fluid | 10 | 2012 | 638 | 0.270 |
Why?
|
| Emergency Medical Services | 2 | 2012 | 684 | 0.270 |
Why?
|
| Severity of Illness Index | 10 | 2018 | 2933 | 0.260 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 241 | 0.260 |
Why?
|
| Cause of Death | 3 | 2017 | 472 | 0.260 |
Why?
|
| Prognosis | 11 | 2016 | 4330 | 0.260 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 528 | 0.260 |
Why?
|
| Proxy | 2 | 2021 | 36 | 0.260 |
Why?
|
| Smoking Cessation | 1 | 2011 | 441 | 0.250 |
Why?
|
| Benzodiazepines | 2 | 2025 | 168 | 0.250 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 7 | 0.250 |
Why?
|
| Specialties, Nursing | 1 | 2006 | 9 | 0.250 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 202 | 0.250 |
Why?
|
| Respiratory Tract Infections | 2 | 2008 | 396 | 0.250 |
Why?
|
| Research Design | 4 | 2026 | 1139 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 2028 | 0.240 |
Why?
|
| Blood Gas Analysis | 2 | 2017 | 82 | 0.240 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2018 | 248 | 0.240 |
Why?
|
| Surgical Procedures, Operative | 1 | 2009 | 271 | 0.240 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 127 | 0.240 |
Why?
|
| Follow-Up Studies | 9 | 2016 | 5428 | 0.240 |
Why?
|
| Pulmonary Edema | 3 | 2013 | 105 | 0.240 |
Why?
|
| Quality of Life | 10 | 2026 | 3211 | 0.230 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 1103 | 0.230 |
Why?
|
| Disability Evaluation | 5 | 2016 | 311 | 0.230 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2008 | 196 | 0.230 |
Why?
|
| Antitubercular Agents | 1 | 2007 | 208 | 0.220 |
Why?
|
| Mental Disorders | 1 | 2014 | 1171 | 0.220 |
Why?
|
| Dentin, Secondary | 1 | 2005 | 1 | 0.220 |
Why?
|
| Dentinogenesis | 1 | 2005 | 1 | 0.220 |
Why?
|
| Analysis of Variance | 3 | 2018 | 1300 | 0.220 |
Why?
|
| Mentors | 4 | 2015 | 217 | 0.220 |
Why?
|
| Propofol | 1 | 2025 | 85 | 0.210 |
Why?
|
| Feasibility Studies | 3 | 2024 | 1115 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 337 | 0.210 |
Why?
|
| Neuromuscular Diseases | 1 | 2006 | 145 | 0.210 |
Why?
|
| Extracellular Matrix | 3 | 2015 | 563 | 0.210 |
Why?
|
| Patient Care | 1 | 2025 | 120 | 0.210 |
Why?
|
| Education, Continuing | 3 | 2015 | 42 | 0.210 |
Why?
|
| Quantum Theory | 1 | 2005 | 86 | 0.210 |
Why?
|
| Metalloendopeptidases | 3 | 2001 | 63 | 0.210 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 381 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2008 | 2668 | 0.200 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 3418 | 0.200 |
Why?
|
| Inflammation | 3 | 2017 | 2884 | 0.200 |
Why?
|
| Liver Transplantation | 1 | 2011 | 827 | 0.200 |
Why?
|
| Education, Medical, Graduate | 1 | 2008 | 562 | 0.190 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2002 | 19 | 0.190 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2003 | 30 | 0.190 |
Why?
|
| Cost of Illness | 2 | 2020 | 324 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 1491 | 0.190 |
Why?
|
| Interferons | 2 | 2016 | 186 | 0.190 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2003 | 95 | 0.190 |
Why?
|
| Oximetry | 3 | 2024 | 125 | 0.190 |
Why?
|
| Multimorbidity | 1 | 2023 | 65 | 0.180 |
Why?
|
| Permeability | 3 | 2013 | 169 | 0.180 |
Why?
|
| Prone Position | 1 | 2022 | 25 | 0.180 |
Why?
|
| Muscular Diseases | 2 | 2017 | 109 | 0.180 |
Why?
|
| Organizations | 1 | 2022 | 28 | 0.180 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 1271 | 0.180 |
Why?
|
| Personnel Turnover | 1 | 2022 | 40 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2010 | 664 | 0.170 |
Why?
|
| Propensity Score | 3 | 2022 | 377 | 0.170 |
Why?
|
| Curriculum | 3 | 2020 | 1074 | 0.170 |
Why?
|
| Occupational Therapists | 1 | 2021 | 9 | 0.170 |
Why?
|
| Publishing | 1 | 2003 | 114 | 0.170 |
Why?
|
| Motivation | 3 | 2015 | 602 | 0.170 |
Why?
|
| Lung Injury | 2 | 2015 | 249 | 0.170 |
Why?
|
| Occupational Health | 2 | 2016 | 213 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 712 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2003 | 288 | 0.170 |
Why?
|
| Psychosocial Support Systems | 1 | 2021 | 16 | 0.170 |
Why?
|
| Double-Blind Method | 7 | 2014 | 2064 | 0.160 |
Why?
|
| Interleukin-8 | 3 | 2018 | 269 | 0.160 |
Why?
|
| Maxillofacial Development | 2 | 1997 | 20 | 0.160 |
Why?
|
| Collagenases | 1 | 2000 | 22 | 0.160 |
Why?
|
| Neutrophils | 3 | 2017 | 1127 | 0.160 |
Why?
|
| Compassion Fatigue | 1 | 2021 | 30 | 0.160 |
Why?
|
| Financing, Personal | 1 | 2020 | 27 | 0.160 |
Why?
|
| Decision Trees | 1 | 2020 | 78 | 0.160 |
Why?
|
| Schools, Nursing | 1 | 2020 | 13 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 371 | 0.160 |
Why?
|
| Professional Role | 1 | 2021 | 170 | 0.150 |
Why?
|
| Radiography, Thoracic | 3 | 2014 | 172 | 0.150 |
Why?
|
| Hypoxia | 3 | 2017 | 1199 | 0.150 |
Why?
|
| Research | 1 | 2003 | 431 | 0.150 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 1197 | 0.150 |
Why?
|
| Preoperative Care | 2 | 2013 | 380 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2025 | 1154 | 0.150 |
Why?
|
| Adaptation, Physiological | 2 | 2021 | 560 | 0.150 |
Why?
|
| Australia | 2 | 2014 | 291 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 2602 | 0.140 |
Why?
|
| Program Development | 3 | 2015 | 368 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2005 | 878 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2012 | 536 | 0.140 |
Why?
|
| Smoke-Free Policy | 1 | 2018 | 13 | 0.140 |
Why?
|
| Sex Factors | 6 | 2018 | 2110 | 0.140 |
Why?
|
| Foundations | 1 | 2018 | 27 | 0.140 |
Why?
|
| Macrolides | 1 | 2019 | 67 | 0.140 |
Why?
|
| Infection Control | 1 | 2020 | 173 | 0.140 |
Why?
|
| Tobacco Industry | 1 | 2018 | 25 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2005 | 956 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2019 | 54 | 0.140 |
Why?
|
| Case-Control Studies | 9 | 2018 | 3634 | 0.140 |
Why?
|
| Vecuronium Bromide | 1 | 2018 | 8 | 0.140 |
Why?
|
| Emergency Service, Hospital | 3 | 2017 | 2383 | 0.140 |
Why?
|
| Pulmonary Ventilation | 2 | 2018 | 82 | 0.140 |
Why?
|
| Social Responsibility | 1 | 2018 | 53 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2017 | 2805 | 0.140 |
Why?
|
| Pandemics | 3 | 2022 | 1711 | 0.140 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 23 | 0.140 |
Why?
|
| Career Mobility | 2 | 2015 | 68 | 0.130 |
Why?
|
| Heart Failure, Systolic | 1 | 2018 | 26 | 0.130 |
Why?
|
| Cardiologists | 1 | 2018 | 45 | 0.130 |
Why?
|
| Young Adult | 10 | 2021 | 14254 | 0.130 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 390 | 0.130 |
Why?
|
| Staff Development | 2 | 2015 | 63 | 0.130 |
Why?
|
| Capillaries | 2 | 2009 | 125 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2017 | 46 | 0.130 |
Why?
|
| Inservice Training | 2 | 2015 | 118 | 0.130 |
Why?
|
| Age Factors | 5 | 2018 | 3346 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2008 | 1269 | 0.130 |
Why?
|
| Physicians, Women | 1 | 2019 | 90 | 0.130 |
Why?
|
| von Willebrand Factor | 1 | 2018 | 85 | 0.130 |
Why?
|
| Dyspnea | 1 | 2019 | 250 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2018 | 115 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 289 | 0.130 |
Why?
|
| Heparin | 1 | 2019 | 247 | 0.130 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 1327 | 0.130 |
Why?
|
| Disintegrins | 1 | 1997 | 6 | 0.130 |
Why?
|
| Bayes Theorem | 1 | 2019 | 421 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2021 | 461 | 0.120 |
Why?
|
| Myosin-Light-Chain Kinase | 2 | 2007 | 19 | 0.120 |
Why?
|
| Psychology, Industrial | 1 | 2016 | 2 | 0.120 |
Why?
|
| Emotions | 2 | 2021 | 577 | 0.120 |
Why?
|
| Hospitals, University | 2 | 2009 | 176 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2023 | 2181 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 3937 | 0.120 |
Why?
|
| Subacute Care | 1 | 2017 | 84 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 948 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2016 | 1378 | 0.120 |
Why?
|
| Pamphlets | 1 | 2016 | 26 | 0.120 |
Why?
|
| Protein Precursors | 1 | 1997 | 136 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2017 | 193 | 0.120 |
Why?
|
| Peer Group | 2 | 2015 | 256 | 0.120 |
Why?
|
| Electrophysiological Phenomena | 1 | 2016 | 59 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 297 | 0.120 |
Why?
|
| Georgia | 3 | 2005 | 79 | 0.120 |
Why?
|
| Animals | 17 | 2017 | 38101 | 0.120 |
Why?
|
| Intersectoral Collaboration | 1 | 2016 | 64 | 0.120 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 297 | 0.110 |
Why?
|
| RNA Splicing | 1 | 2017 | 284 | 0.110 |
Why?
|
| Education, Graduate | 1 | 2015 | 35 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 364 | 0.110 |
Why?
|
| Exercise Therapy | 1 | 2020 | 475 | 0.110 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 400 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 1217 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
|
| Neurophysiological Monitoring | 1 | 2015 | 9 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 3 | 2026 | 413 | 0.110 |
Why?
|
| Alternative Splicing | 1 | 2017 | 248 | 0.110 |
Why?
|
| France | 2 | 2005 | 40 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2019 | 587 | 0.110 |
Why?
|
| Genome, Human | 1 | 1997 | 422 | 0.110 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 121 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 2601 | 0.110 |
Why?
|
| Hospitals, Community | 1 | 2015 | 67 | 0.110 |
Why?
|
| Seasons | 2 | 2008 | 538 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2018 | 788 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 605 | 0.110 |
Why?
|
| Craniotomy | 1 | 2015 | 84 | 0.110 |
Why?
|
| Nurse's Role | 1 | 2016 | 149 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2023 | 1898 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2016 | 153 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 328 | 0.100 |
Why?
|
| Intracranial Pressure | 1 | 2015 | 65 | 0.100 |
Why?
|
| Chronic Disease | 5 | 2018 | 1812 | 0.100 |
Why?
|
| Health Surveys | 2 | 2009 | 520 | 0.100 |
Why?
|
| Peroneal Nerve | 1 | 2014 | 18 | 0.100 |
Why?
|
| Sural Nerve | 1 | 2014 | 22 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 161 | 0.100 |
Why?
|
| Methylprednisolone | 1 | 2014 | 59 | 0.100 |
Why?
|
| Ethanol | 2 | 2010 | 631 | 0.100 |
Why?
|
| Glasgow Coma Scale | 1 | 2015 | 218 | 0.100 |
Why?
|
| Forms and Records Control | 1 | 2013 | 20 | 0.100 |
Why?
|
| Statistics, Nonparametric | 3 | 2004 | 428 | 0.100 |
Why?
|
| Social Support | 1 | 2018 | 651 | 0.100 |
Why?
|
| Epithelial Cells | 2 | 2017 | 1134 | 0.100 |
Why?
|
| Survival Rate | 4 | 2011 | 2094 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2016 | 259 | 0.100 |
Why?
|
| Neurologic Examination | 1 | 2014 | 132 | 0.100 |
Why?
|
| Electrophysiology | 1 | 2014 | 218 | 0.100 |
Why?
|
| Public Health | 1 | 2018 | 574 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2019 | 748 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2770 | 0.100 |
Why?
|
| Melatonin | 1 | 2014 | 163 | 0.100 |
Why?
|
| Ventilator Weaning | 1 | 2013 | 40 | 0.100 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2013 | 42 | 0.090 |
Why?
|
| Forecasting | 1 | 2014 | 390 | 0.090 |
Why?
|
| Macrophages, Alveolar | 3 | 2010 | 373 | 0.090 |
Why?
|
| Oxidative Stress | 2 | 2012 | 1360 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2016 | 1083 | 0.090 |
Why?
|
| Heart Failure | 1 | 2026 | 2326 | 0.090 |
Why?
|
| Tape Recording | 1 | 2012 | 10 | 0.090 |
Why?
|
| Hemorrhage | 2 | 2019 | 822 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2014 | 286 | 0.090 |
Why?
|
| Academic Medical Centers | 2 | 2012 | 554 | 0.090 |
Why?
|
| Serotonin | 1 | 2014 | 298 | 0.090 |
Why?
|
| Bed Rest | 1 | 2012 | 14 | 0.090 |
Why?
|
| Perception | 1 | 2015 | 378 | 0.090 |
Why?
|
| Outpatients | 1 | 2016 | 447 | 0.090 |
Why?
|
| Interview, Psychological | 1 | 2012 | 95 | 0.090 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2012 | 24 | 0.090 |
Why?
|
| Neuregulin-1 | 1 | 2012 | 49 | 0.090 |
Why?
|
| Uteroglobin | 2 | 2014 | 31 | 0.090 |
Why?
|
| Observer Variation | 1 | 2012 | 357 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2011 | 26 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1582 | 0.090 |
Why?
|
| Data Collection | 2 | 2011 | 643 | 0.080 |
Why?
|
| Counseling | 1 | 2014 | 401 | 0.080 |
Why?
|
| Albuterol | 1 | 2011 | 76 | 0.080 |
Why?
|
| Nursing Homes | 1 | 2013 | 174 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2017 | 686 | 0.080 |
Why?
|
| Pediatric Nursing | 1 | 2011 | 44 | 0.080 |
Why?
|
| Professional-Family Relations | 1 | 2012 | 154 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 849 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 484 | 0.080 |
Why?
|
| Telemedicine | 1 | 2020 | 967 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2012 | 1368 | 0.080 |
Why?
|
| Risk | 3 | 2018 | 923 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2013 | 483 | 0.080 |
Why?
|
| Comparative Effectiveness Research | 1 | 2011 | 169 | 0.080 |
Why?
|
| Adolescent | 7 | 2022 | 22577 | 0.080 |
Why?
|
| Self Report | 1 | 2014 | 876 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 1 | 2009 | 95 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2017 | 368 | 0.080 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2010 | 98 | 0.080 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 80 | 0.070 |
Why?
|
| Enteral Nutrition | 1 | 2012 | 217 | 0.070 |
Why?
|
| Lung Compliance | 1 | 2009 | 42 | 0.070 |
Why?
|
| Physician's Role | 1 | 2011 | 225 | 0.070 |
Why?
|
| Patient Selection | 1 | 2013 | 739 | 0.070 |
Why?
|
| Thermodilution | 2 | 2008 | 16 | 0.070 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 2 | 2024 | 103 | 0.070 |
Why?
|
| Trauma Centers | 2 | 2009 | 466 | 0.070 |
Why?
|
| Physician-Nurse Relations | 1 | 2009 | 18 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2399 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2020 | 360 | 0.070 |
Why?
|
| Leisure Activities | 1 | 2009 | 31 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 480 | 0.070 |
Why?
|
| Energy Intake | 1 | 2012 | 512 | 0.070 |
Why?
|
| Walking | 1 | 2013 | 545 | 0.070 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2008 | 13 | 0.070 |
Why?
|
| Radionuclide Imaging | 2 | 2008 | 116 | 0.070 |
Why?
|
| Phagocytosis | 1 | 2010 | 296 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2011 | 279 | 0.070 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2009 | 80 | 0.070 |
Why?
|
| Nurse Administrators | 1 | 2009 | 42 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 843 | 0.070 |
Why?
|
| Half-Life | 1 | 2008 | 155 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 1925 | 0.070 |
Why?
|
| Psychometrics | 1 | 2012 | 732 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2011 | 305 | 0.070 |
Why?
|
| Pulmonary Artery | 2 | 2013 | 1129 | 0.070 |
Why?
|
| Hospitals, Urban | 2 | 2018 | 142 | 0.070 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2007 | 12 | 0.060 |
Why?
|
| Mandible | 1 | 1988 | 73 | 0.060 |
Why?
|
| Health Behavior | 1 | 2013 | 791 | 0.060 |
Why?
|
| Sleep Wake Disorders | 1 | 2011 | 314 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2016 | 1296 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 205 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2007 | 71 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 611 | 0.060 |
Why?
|
| Mental Recall | 2 | 2021 | 223 | 0.060 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2007 | 65 | 0.060 |
Why?
|
| Plasma | 1 | 2009 | 223 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2007 | 78 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2008 | 72 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2011 | 454 | 0.060 |
Why?
|
| Social Environment | 1 | 2009 | 252 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 133 | 0.060 |
Why?
|
| Models, Biological | 3 | 2009 | 1764 | 0.060 |
Why?
|
| Caregivers | 1 | 2016 | 1074 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2017 | 5224 | 0.060 |
Why?
|
| Pharmacoepidemiology | 2 | 2019 | 23 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 5992 | 0.060 |
Why?
|
| Morbidity | 1 | 2007 | 322 | 0.060 |
Why?
|
| Fibronectins | 1 | 2007 | 136 | 0.060 |
Why?
|
| Hemodynamics | 3 | 2009 | 1118 | 0.060 |
Why?
|
| Hypoproteinemia | 1 | 2005 | 5 | 0.060 |
Why?
|
| Gene Expression | 1 | 2010 | 1478 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2009 | 1165 | 0.060 |
Why?
|
| England | 1 | 2005 | 110 | 0.060 |
Why?
|
| Furosemide | 1 | 2005 | 37 | 0.060 |
Why?
|
| Electronic Health Records | 1 | 2013 | 1202 | 0.060 |
Why?
|
| Polysomnography | 1 | 2006 | 239 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2001 | 821 | 0.060 |
Why?
|
| Diuretics | 1 | 2005 | 68 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2005 | 57 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 255 | 0.060 |
Why?
|
| Probability | 1 | 2006 | 308 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 1261 | 0.050 |
Why?
|
| Age Distribution | 1 | 2006 | 404 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2006 | 388 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2010 | 4151 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2005 | 147 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 361 | 0.050 |
Why?
|
| Wounds, Penetrating | 1 | 2005 | 72 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2007 | 216 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 1475 | 0.050 |
Why?
|
| ADAM17 Protein | 3 | 2001 | 42 | 0.050 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 206 | 0.050 |
Why?
|
| Meditation | 1 | 2024 | 34 | 0.050 |
Why?
|
| Respiratory Function Tests | 2 | 2016 | 544 | 0.050 |
Why?
|
| E-Selectin | 1 | 2004 | 61 | 0.050 |
Why?
|
| ADAM Proteins | 3 | 2001 | 64 | 0.050 |
Why?
|
| New Zealand | 1 | 2004 | 55 | 0.050 |
Why?
|
| Biomechanical Phenomena | 2 | 1997 | 860 | 0.050 |
Why?
|
| Phenotype | 2 | 2025 | 3170 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 770 | 0.050 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2023 | 24 | 0.050 |
Why?
|
| Bone and Bones | 2 | 1997 | 318 | 0.050 |
Why?
|
| Cell Separation | 2 | 2016 | 306 | 0.050 |
Why?
|
| Oxygen | 3 | 2024 | 981 | 0.050 |
Why?
|
| Analgesia | 1 | 2024 | 106 | 0.050 |
Why?
|
| Mice | 6 | 2011 | 18355 | 0.050 |
Why?
|
| Catalytic Domain | 2 | 2000 | 234 | 0.050 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2010 | 692 | 0.050 |
Why?
|
| Cytokines | 3 | 2017 | 2069 | 0.050 |
Why?
|
| Washington | 1 | 2003 | 149 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 2 | 2007 | 474 | 0.050 |
Why?
|
| Microtubules | 1 | 2005 | 265 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 971 | 0.050 |
Why?
|
| Exercise | 1 | 2014 | 2205 | 0.050 |
Why?
|
| DNA | 2 | 2000 | 1437 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2008 | 835 | 0.050 |
Why?
|
| Kinetics | 3 | 2000 | 1568 | 0.040 |
Why?
|
| Substrate Specificity | 2 | 2000 | 387 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2005 | 321 | 0.040 |
Why?
|
| Formamides | 1 | 2001 | 8 | 0.040 |
Why?
|
| Vasopressins | 1 | 2022 | 61 | 0.040 |
Why?
|
| North America | 1 | 2022 | 304 | 0.040 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2001 | 17 | 0.040 |
Why?
|
| Apoptosis | 1 | 2010 | 2444 | 0.040 |
Why?
|
| Aftercare | 1 | 2023 | 222 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2006 | 2968 | 0.040 |
Why?
|
| Norepinephrine | 1 | 2022 | 201 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 150 | 0.040 |
Why?
|
| Moral Obligations | 1 | 2021 | 15 | 0.040 |
Why?
|
| Critical Care Outcomes | 1 | 2020 | 11 | 0.040 |
Why?
|
| Status Asthmaticus | 1 | 2020 | 13 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2000 | 25 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2000 | 22 | 0.040 |
Why?
|
| Allied Health Personnel | 1 | 2021 | 53 | 0.040 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2000 | 27 | 0.040 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2000 | 15 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2003 | 322 | 0.040 |
Why?
|
| Antimalarials | 1 | 2020 | 35 | 0.040 |
Why?
|
| Rural Population | 1 | 2025 | 661 | 0.040 |
Why?
|
| Peptide Library | 1 | 2000 | 91 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 1101 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2020 | 98 | 0.040 |
Why?
|
| Disease Progression | 2 | 2020 | 2865 | 0.040 |
Why?
|
| Veterans Health | 1 | 2021 | 190 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 376 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 318 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2001 | 267 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 173 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 1036 | 0.040 |
Why?
|
| Minority Groups | 1 | 2021 | 285 | 0.040 |
Why?
|
| Income | 1 | 2020 | 203 | 0.040 |
Why?
|
| Smoking | 3 | 2015 | 1477 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 782 | 0.040 |
Why?
|
| Collagen | 2 | 2000 | 457 | 0.040 |
Why?
|
| Education, Nursing | 1 | 2020 | 92 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2020 | 244 | 0.030 |
Why?
|
| Tennessee | 1 | 2018 | 57 | 0.030 |
Why?
|
| Species Specificity | 2 | 2011 | 546 | 0.030 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2018 | 57 | 0.030 |
Why?
|
| Observation | 2 | 2011 | 54 | 0.030 |
Why?
|
| Child | 5 | 2022 | 22740 | 0.030 |
Why?
|
| Genotype | 1 | 2023 | 1857 | 0.030 |
Why?
|
| Sexism | 1 | 2019 | 68 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2000 | 1184 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2018 | 49 | 0.030 |
Why?
|
| Minnesota | 1 | 2018 | 168 | 0.030 |
Why?
|
| Periosteum | 1 | 1997 | 14 | 0.030 |
Why?
|
| Mechanoreceptors | 1 | 1997 | 15 | 0.030 |
Why?
|
| RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 778 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2020 | 311 | 0.030 |
Why?
|
| Growth | 1 | 1997 | 49 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2018 | 130 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 204 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 979 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 2131 | 0.030 |
Why?
|
| Gap Junctions | 1 | 1997 | 67 | 0.030 |
Why?
|
| Morphogenesis | 1 | 1997 | 171 | 0.030 |
Why?
|
| Binding Sites | 2 | 1997 | 1311 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 196 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 121 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 1420 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1997 | 244 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 387 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 2883 | 0.030 |
Why?
|
| RNA Precursors | 1 | 2017 | 154 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2016 | 30 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1997 | 538 | 0.030 |
Why?
|
| Azasteroids | 1 | 1995 | 5 | 0.030 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 1995 | 16 | 0.030 |
Why?
|
| Environment | 1 | 1997 | 293 | 0.030 |
Why?
|
| Finasteride | 1 | 1995 | 33 | 0.030 |
Why?
|
| Cell Communication | 1 | 2017 | 327 | 0.030 |
Why?
|
| Radiation Effects | 1 | 1975 | 7 | 0.030 |
Why?
|
| Cosmic Radiation | 1 | 1975 | 5 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2016 | 193 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 381 | 0.030 |
Why?
|
| Models, Educational | 1 | 2015 | 90 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 93 | 0.030 |
Why?
|
| Capacity Building | 1 | 2015 | 62 | 0.030 |
Why?
|
| Genome | 1 | 1997 | 305 | 0.030 |
Why?
|
| Cell Line | 2 | 1999 | 2823 | 0.030 |
Why?
|
| Tooth | 1 | 1975 | 45 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2018 | 544 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2016 | 144 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1995 | 295 | 0.030 |
Why?
|
| Mouth | 1 | 1975 | 86 | 0.030 |
Why?
|
| Haplotypes | 2 | 2007 | 500 | 0.030 |
Why?
|
| Fibroblasts | 2 | 2013 | 1028 | 0.030 |
Why?
|
| Peptides | 1 | 2000 | 999 | 0.030 |
Why?
|
| Space Flight | 1 | 1975 | 70 | 0.030 |
Why?
|
| Nitrites | 1 | 2014 | 88 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 201 | 0.030 |
Why?
|
| Swine | 1 | 1997 | 826 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 381 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 2 | 2013 | 78 | 0.030 |
Why?
|
| Nitrates | 1 | 2014 | 96 | 0.030 |
Why?
|
| Mental Competency | 1 | 2013 | 27 | 0.020 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.020 |
Why?
|
| Total Lung Capacity | 1 | 2013 | 29 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 1454 | 0.020 |
Why?
|
| Fibrosis | 1 | 2015 | 561 | 0.020 |
Why?
|
| Electrodiagnosis | 1 | 2012 | 17 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2013 | 292 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2013 | 155 | 0.020 |
Why?
|
| Respiratory Muscles | 1 | 2012 | 37 | 0.020 |
Why?
|
| Documentation | 1 | 2013 | 199 | 0.020 |
Why?
|
| Brain | 1 | 2024 | 2969 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2012 | 67 | 0.020 |
Why?
|
| Phytotherapy | 1 | 2012 | 74 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2012 | 168 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2011 | 43 | 0.020 |
Why?
|
| Hospital Units | 1 | 2011 | 32 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2011 | 81 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2017 | 517 | 0.020 |
Why?
|
| Epithelium | 1 | 2012 | 311 | 0.020 |
Why?
|
| Muscular Atrophy | 1 | 2012 | 87 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 779 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 736 | 0.020 |
Why?
|
| Microbial Viability | 1 | 2011 | 83 | 0.020 |
Why?
|
| Muscle Fatigue | 1 | 2012 | 98 | 0.020 |
Why?
|
| Superoxides | 1 | 2011 | 198 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2010 | 89 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 428 | 0.020 |
Why?
|
| Night Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Neoplasms | 1 | 2006 | 2913 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 141 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 478 | 0.020 |
Why?
|
| After-Hours Care | 1 | 2010 | 17 | 0.020 |
Why?
|
| Community Participation | 1 | 2011 | 123 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 1166 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 264 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 76 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2011 | 571 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2010 | 56 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2010 | 82 | 0.020 |
Why?
|
| Amides | 1 | 2010 | 101 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1997 | 2050 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 382 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2014 | 892 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 1995 | 560 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1777 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2012 | 204 | 0.020 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2014 | 376 | 0.020 |
Why?
|
| Parity | 1 | 2009 | 111 | 0.020 |
Why?
|
| Viruses | 1 | 2011 | 166 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2010 | 370 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2008 | 115 | 0.020 |
Why?
|
| Antioxidants | 1 | 2012 | 550 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 342 | 0.020 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2008 | 49 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2001 | 563 | 0.020 |
Why?
|
| Maxilla | 1 | 1967 | 36 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2012 | 780 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2011 | 558 | 0.020 |
Why?
|
| Breath Tests | 1 | 2007 | 77 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2007 | 29 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2008 | 283 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 533 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2009 | 430 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 106 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2008 | 251 | 0.020 |
Why?
|
| Body Height | 1 | 2008 | 203 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 145 | 0.020 |
Why?
|
| Body Fluids | 1 | 2007 | 71 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 858 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 963 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 95 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 532 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 335 | 0.010 |
Why?
|
| Pyridines | 1 | 2010 | 609 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2007 | 227 | 0.010 |
Why?
|
| Urban Population | 1 | 2008 | 494 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 37 | 0.010 |
Why?
|
| SEER Program | 1 | 2006 | 230 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 74 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 1512 | 0.010 |
Why?
|
| Introns | 1 | 2006 | 256 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 364 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 399 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 972 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2007 | 1069 | 0.010 |
Why?
|
| Genomics | 1 | 2008 | 830 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2005 | 353 | 0.010 |
Why?
|
| Dogs | 1 | 2001 | 478 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4568 | 0.010 |
Why?
|
| Insecta | 1 | 1999 | 71 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1999 | 191 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1999 | 254 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 927 | 0.010 |
Why?
|
| Pregnancy | 1 | 2009 | 7216 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1999 | 709 | 0.010 |
Why?
|
| Mathematics | 1 | 1995 | 101 | 0.010 |
Why?
|
| Tongue | 1 | 1975 | 77 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 1975 | 85 | 0.010 |
Why?
|
| Progesterone | 1 | 1995 | 215 | 0.010 |
Why?
|
| Muscles | 1 | 1975 | 330 | 0.010 |
Why?
|
| Ligands | 1 | 1995 | 668 | 0.010 |
Why?
|
| Thermodynamics | 1 | 1995 | 419 | 0.010 |
Why?
|
| Rats | 1 | 2001 | 5585 | 0.010 |
Why?
|
| Testosterone | 1 | 1995 | 416 | 0.010 |
Why?
|
| Maxillary Nerve | 1 | 1967 | 3 | 0.000 |
Why?
|
| Dentition, Mixed | 1 | 1967 | 2 | 0.000 |
Why?
|
| Dentition, Permanent | 1 | 1967 | 5 | 0.000 |
Why?
|
| Tooth, Deciduous | 1 | 1967 | 19 | 0.000 |
Why?
|
| Sella Turcica | 1 | 1967 | 17 | 0.000 |
Why?
|
| Sphenoid Bone | 1 | 1967 | 15 | 0.000 |
Why?
|
| Cephalometry | 1 | 1967 | 30 | 0.000 |
Why?
|
| Skull Base | 1 | 1967 | 55 | 0.000 |
Why?
|
| Orbit | 1 | 1967 | 66 | 0.000 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1976 | 11 | 0.000 |
Why?
|
| Lung Volume Measurements | 1 | 1976 | 46 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1976 | 719 | 0.000 |
Why?
|